U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07544862) titled 'A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)' on April 16.
Brief Summary: This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Study Start Date: June, 2026
Study Type: OBSERVATIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
BIOLOGICAL: Stapokibart
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chengdu Kangnuoxing Biopharma,Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....